1Stove CK,Pham QX,Erwin AL,et al.Complete genome sequence of Pseudomonas aer-uginosa PAO1 an opportunistic pathogen[J].Nature,2000,406:959.
2Bradford PA.Extended-spectrum beta-lactamases in the 21st century:characterization,epidemiology,and detection of this important resistance threat[J].Clin Microbiol Rev,2001,14(4):933-951.
4Then RL.Ability of newer beta-lactam antibiotics to induce betalactamase production in Enterobacter cloacae[J].Eur J Clin Micrebiol,2007,6(4):451-455.
5Hocquet D,Roussel Delvallez M,Cavallo JD,et al.MexAB-OprM and MexXY-overproducing mutants are very prevalent among clinical strains of pseudomonas aeruginosa with reduced susceptibility to ticarcillin[J].Antimicrob Agents Chemother,2007,51(4):1582-1583.
6Jo JTH,Brinkman FSL,Hancock REW.Aminogly coside effiux in pseudomonas aeru-ginosa:involvement of novel outer membrane proteins[J].Antimicrob Chemother,2003,47(3):1101-1111.
7Farra A,Islam S,Stralfors A,et al.Role of outer membrane protein OprD and penicillin binding proteins in resistance of pseudomonas aeruginosa to imipenemand meropenem[J].Int JAntimicrob Agents,2008,31(5):427-433.
8Giske CG,Buar L,Sundsfjord A,et al.Alterations of porin,pumps,and penicillin-binding proteins in carbapenem resistant clinical isolates of pseudomon as aeruginosa[J].Microb Drug Resist,2008,14(1):23-30.
9Sanders CC,Bradford PA,Ehrhardt AF,et al.Penicillin-binding proteins and induction of AmpC beta-lactamase[J].Antimicrob Agents Chemother,1997,41(9):2013-2015.
10Horowitz DS,Wang JC.Mapping the active site tyrosine of Escherichia coil DNA gyrase[J].J Biol Chem,1987,262(11):5339-5344.
2Chanawong A,M'Zali FH,Heritage J,et al.SHV-12,SHV-5,SHV-2a and VEB-1 extended-spectrum beta-lactamases in Gram-negative bacteria isolated in a university hospital in Thailand.J Antimicrob Chemother,2001,48(6):839-852.
3Vahaboglu H,Ozturk R,Aygun G,et al.Widespread detection of PER-1-type extended-spectrum beta-lactamases among nosocomial acinetobacter and Pseudomonas aeruginosa isolates in Turkey:a nationwide multicenter study.Antimicrob Agents Chemother,1997,41 (10):2265-2269.
4Naas T,Poirel L,Karim A,et al.Molecular characterization of In50,a class 1 integron encoding the gene for the extended-spectrum beta-lactamase VEB-1 in Pseudomonas aeruginosa.FEMS Microbiol Lett,1999,176(2):411-419.
5Aubert D,Girlich D,Naas T,et al.Functional and structural characterization of the genetic environment of an extended-spectrum beta-lactamase blaVEB gene from a Pseudomonas aeruginosa isolate obtained in India.Antimicrob.Agents Chemother,2004,48(9):3284-3290.
6Girlich D,Naas T,Leelaporn A,et al.Nosocomial spread of the integron-located veb-1-like cassette encoding an extended-pectrum beta-lactamase in Pseudomonas aeruginosa in Thailand.Clin Infect Dis,2002,34(5):603-611.
7Mugnier P,Casin I,Bouthors AT,et al.Novel OXA-10-derived extended-spectrum beta-lactamases selected in vivo or in vitro.Antimicrob Agents Chemother,1998,42(12):3113-3116.
8Poirel L,Girlich D,Naas T,et al.OXA-28,an extended-spectrum variant of OXA-10 beta-lactamase from Pseudomonas aeruginosa and its plasmid-and integron-located gene.Antimicrob Agents Chemother,2001,45(2):447-453.
9Poirel L,Gerome P,De Champs C,et al.Integron-located oxa-32 gene cassette encoding an extended-spectrum variant of OXA-2 beta-lactamase from Pseudomonas aeruginosa.Antimicrob Agents Chemother,2002,46(2):566-569.
10Aubert D,Poirel L,Ali AB,et al.OXA-35 is an OXA-10-related betalactamase from Pseudomonas aeruginosa.J Antimicrob Chemother,2001,48(5):717-721.
1Thong KL, Lai MY, Teh C S J, et al. Simultaneous detection of methicil- lin-resistant Staphylococcus aureus, Aeinetobaeter baumannii, Esche- richia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa by multiplex PCR[ J]. Trop Biomed,2011,28( 1 ) :21-31.
2Su TY, Ye JJ, Hsu PC, et al. Clinical characteristics and risk factors for mortality in cefepime-resistant pseudomonas aeruginosa bacteremia [J]. J Microbiol Immunol Infect,2015,48(2): 175-182.
3Morata L, Cobos-Trigueros N, Martfnez JA, et al. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of pseudomonas aeruginosa bacteremia [ J ]. Antimicrobial Agents and Chemotherapy,2012,56 (9) :4833-4837.
4Tumbarello M, Repetto E, Treearichi EM, et al. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections : risk factors and mor- tality[ J ]. Epidemiol Infect,2011,139 ( 11 ) : 1740-1749.
5Li H, Luo YF, Williams B J, et al. Structure and function of OprD pro- tein in Pseudomonas aeruginosa: from antibiotic resistance to novel therapies[J]. Int J Med Microbiol,2012,302(2) :63-68.
6Lee JY, Ko KS. OprD mutations and inactivation, expression of effiux pumps and AmpC, and metallo-13-1actamases in carbapenem-resistant Pseudomonas aeruginosa isolates from South Korea[ J]. Int J Antimi- crob Agents,2012,40(2) :168-172.
